Best Undervalued Stocks To Own For 2018

tags:NKTR,LXRX,CYBR,SANW,SIGI,

Chipmaker QUALCOMM, Inc. (NASDAQ:QCOM) has been on a wild ride over the past several months. The shares were in a down-trend for most of 2017 until Broadcom Inc (NASDAQ:AVGO) acquisition rumors emerged in October, sending QCOM stock from $50 to $70 in a hurry.

But then U.S. President Donald Trump essentially blocked AVGO’s acquisition attempts. Merger talks went cold. Qualcomm stock dropped. The decline continues, due to a confluence of headwinds, ranging from Chinese regulation to costly lawsuits to weak smartphone demand.

Now, QCOM stock is back at that $50 level of October 2017.

Time to buy? Getting close, but not yet. The fundamentals imply this stock isn’t undervalued yet, while the sentiment remains largely negative. Thus, the best move seems like to wait for the dust to settle.

Let’s tak a deeper look.

QCOM Has Been Absorbed In Wildness

The only way to describe what QCOM has been through over the past several months is simply “wild.”

Best Undervalued Stocks To Own For 2018: Nektar Therapeutics(NKTR)

Advisors' Opinion:

• [By Stephan Byrd]

  TRADEMARK VIOLATION NOTICE: “Nektar Therapeutics (NKTR) Trading Down 7%” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3362849/nektar-therapeutics-nktr-trading-down-7.html.

• [By Dan Caplinger]

  Friday was a relatively quiet day on Wall Street, with a split among the most widely followed market benchmarks that sent some up and others down. Slight downticks in oil prices and bond yields marked minor reversals from upward trends earlier in the week, but investors are still watching both energy and bonds closely to see what long-term impact they might have on the stock market. Most attention centered on individual companies, some of which reported good news that sent their shares higher. Dell Technologies (NYSE:DVMT), Nektar Therapeutics (NASDAQ:NKTR), and Westport Fuel Systems (NASDAQ:WPRT) were among the best performers on the day. Here's why they did so well.

• [By Max Byerly]

  HC Wainwright set a $125.00 target price on Nektar Therapeutics (NASDAQ:NKTR) in a report published on Sunday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

• [By Maxx Chatsko]

  Shares of biopharma Nektar Therapeutics (NASDAQ:NKTR) dropped over 11% today after the company released an abstract to be presented at the American Society of Clinical Oncology annual meeting next month that contained a disappointing update for an ongoing clinical trial.

• [By Cory Renauer]

  Even though it's been a rough few years for many of the industry's larger players, some smaller upstarts have produced stunning gains lately. Shares of�Nektar Therapeutics (NASDAQ:NKTR), BeiGene Ltd. (NASDAQ:BGNE), and AveXis Inc. (NASDAQ:AVXS) have risen at least 500% in less than three years.�

Best Undervalued Stocks To Own For 2018: Lexicon Pharmaceuticals, Inc.(LXRX)

Advisors' Opinion:

• [By Shane Hupp]

  Lexicon Pharmaceuticals (NASDAQ:LXRX) – Analysts at Wedbush issued their Q1 2019 earnings per share (EPS) estimates for Lexicon Pharmaceuticals in a note issued to investors on Monday, May 7th. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will earn ($0.28) per share for the quarter. Wedbush currently has a “Outperform” rating and a $40.00 target price on the stock. Wedbush also issued estimates for Lexicon Pharmaceuticals’ Q2 2019 earnings at ($0.25) EPS, Q3 2019 earnings at ($0.13) EPS, Q4 2019 earnings at ($0.06) EPS, FY2020 earnings at $0.53 EPS, FY2021 earnings at $2.22 EPS and FY2022 earnings at $3.81 EPS.

• [By Keith Speights]

  Dividend Yield

  Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88% AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97% Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29% DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77% Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57% Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14% Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22% Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61% Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82% Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64% Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/A

  Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Max Byerly]

  Get a free copy of the Zacks research report on Lexicon Pharmaceuticals (LXRX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: CyberArk Software Ltd.(CYBR)

Advisors' Opinion:

• [By Chris Lange]

  The short interest at CyberArk Software Ltd. (NASDAQ: CYBR) decreased to 697,700 shares from the previous level of 887,900. Shares were trading at $60.24, within a 52-week range of $39.34 to $60.59.

• [By Chris Lange]

  The short interest at CyberArk Software Ltd. (NASDAQ: CYBR) increased to 1.10 million shares from the previous level of 861,800. Shares were trading at $53.34, within a 52-week range of $39.34 to $55.63.

• [By Joe Tenebruso]

  Nearly 90%�of security professionals believe that an enterprise's IT infrastructure is not fully protected unless its privileged accounts are secured, according to a survey by CyberArk Software Ltd.�(NASDAQ:CYBR). This global demand for cybersecurity solutions that safeguard an organization's most sensitive data is helping to fuel CyberArk's growth, as evidenced by its strong first-quarter�results.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on CyberArk (CYBR)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: S&W Seed Company(SANW)

Advisors' Opinion:

• [By Ethan Ryder]

  S&w Seed (NASDAQ:SANW) – Equities researchers at B. Riley decreased their Q3 2019 earnings per share (EPS) estimates for S&w Seed in a research note issued to investors on Thursday, May 10th. B. Riley analyst S. Sherbetchyan now anticipates that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.01. B. Riley has a “Buy” rating and a $5.50 price objective on the stock.

• [By Logan Wallace]

  Get a free copy of the Zacks research report on S&w Seed (SANW)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Undervalued Stocks To Own For 2018: Selective Insurance Group, Inc.(SIGI)

Advisors' Opinion:

• [By Shane Hupp]

  BidaskClub downgraded shares of Selective Insurance (NASDAQ:SIGI) from a hold rating to a sell rating in a report published on Monday.

  A number of other equities research analysts have also issued reports on SIGI. ValuEngine upgraded shares of Selective Insurance from a hold rating to a buy rating in a report on Friday, February 2nd. Keefe, Bruyette & Woods set a $62.00 price target on shares of Selective Insurance and gave the stock a hold rating in a research note on Monday, February 5th. Zacks Investment Research downgraded shares of Selective Insurance from a buy rating to a hold rating in a report on Wednesday, March 14th. Sandler O’Neill reaffirmed a hold rating and set a $61.00 price objective on shares of Selective Insurance in a report on Friday, April 6th. Finally, Boenning Scattergood reaffirmed a hold rating on shares of Selective Insurance in a report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $62.50.

• [By Shane Hupp]

  Selective Insurance (NASDAQ:SIGI) – Boenning Scattergood decreased their Q2 2018 earnings per share estimates for shares of Selective Insurance in a research note issued to investors on Thursday, May 3rd. Boenning Scattergood analyst R. Farnam now expects that the insurance provider will earn $0.83 per share for the quarter, down from their prior estimate of $0.96. Boenning Scattergood has a “Hold” rating on the stock. Boenning Scattergood also issued estimates for Selective Insurance’s Q4 2018 earnings at $1.04 EPS, Q1 2019 earnings at $0.88 EPS, Q2 2019 earnings at $0.85 EPS, Q3 2019 earnings at $0.98 EPS and Q4 2019 earnings at $1.05 EPS.